Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004

Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research